Wells Fargo & Company MN boosted its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 174.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 88,688 shares of the biopharmaceutical company’s stock after acquiring an additional 56,418 shares during the quarter. Wells Fargo & Company MN owned about 0.17% of Theravance Biopharma worth $3,533,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of TBPH. Bank of New York Mellon Corp lifted its position in Theravance Biopharma by 2.6% during the 1st quarter. Bank of New York Mellon Corp now owns 206,023 shares of the biopharmaceutical company’s stock worth $7,586,000 after acquiring an additional 5,188 shares during the period. Swiss National Bank lifted its position in Theravance Biopharma by 1.7% during the 1st quarter. Swiss National Bank now owns 64,442 shares of the biopharmaceutical company’s stock worth $2,373,000 after acquiring an additional 1,100 shares during the period. Parametric Portfolio Associates LLC lifted its position in Theravance Biopharma by 3.3% during the 1st quarter. Parametric Portfolio Associates LLC now owns 14,090 shares of the biopharmaceutical company’s stock worth $519,000 after acquiring an additional 456 shares during the period. Ameritas Investment Partners Inc. raised its stake in shares of Theravance Biopharma by 1,494.3% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,635 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 3,407 shares in the last quarter. Finally, American International Group Inc. raised its stake in shares of Theravance Biopharma by 16.4% during the 1st quarter. American International Group Inc. now owns 24,276 shares of the biopharmaceutical company’s stock worth $894,000 after buying an additional 3,417 shares in the last quarter. 84.54% of the stock is owned by institutional investors.

In other Theravance Biopharma news, CEO Rick E. Winningham acquired 10,000 shares of Theravance Biopharma stock in a transaction dated Friday, August 11th. The stock was acquired at an average cost of $24.50 per share, for a total transaction of $245,000.00. Following the completion of the transaction, the chief executive officer now owns 866,377 shares in the company, valued at approximately $21,226,236.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Bradford J. Shafer sold 14,670 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $30.77, for a total value of $451,395.90. Following the transaction, the executive vice president now owns 134,327 shares of the company’s stock, valued at $4,133,241.79. The disclosure for this sale can be found here. Over the last quarter, insiders have bought 20,000 shares of company stock valued at $494,300. Insiders own 6.10% of the company’s stock.

Theravance Biopharma, Inc. (NASDAQ TBPH) opened at 33.44 on Wednesday. The stock’s market capitalization is $1.80 billion. Theravance Biopharma, Inc. has a 52 week low of $23.15 and a 52 week high of $43.44. The stock’s 50 day moving average price is $32.89 and its 200-day moving average price is $35.50.

COPYRIGHT VIOLATION WARNING: “Wells Fargo & Company MN Buys 56,418 Shares of Theravance Biopharma, Inc. (TBPH)” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/wells-fargo-company-mn-buys-56418-shares-of-theravance-biopharma-inc-tbph/1637946.html.

TBPH has been the subject of a number of analyst reports. Cantor Fitzgerald set a $55.00 target price on Theravance Biopharma and gave the stock a “buy” rating in a research note on Wednesday, July 19th. BidaskClub raised Theravance Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Zacks Investment Research raised Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Tuesday, September 5th. Needham & Company LLC reissued a “buy” rating on shares of Theravance Biopharma in a research note on Wednesday, August 2nd. Finally, ValuEngine raised Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Wednesday, September 13th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $45.17.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma, Inc. (NASDAQ:TBPH).

Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.